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Abstract 
 Background and Aim: Aromatase inhibitors (AIs) and selective 
estrogen receptor modulators (SERMs) are important components of 
adjuvant endocrine therapy in postmenopausal women with estrogen receptor 
positive breast cancer. The aim of our study was to assess the effect of AIs 
and SERMs on bone mineral density (BMD) in Caucasian postmenopausal 
women with breast cancer.  Patients and Methods: 118 postmenopausal 
Caucasian women were enrolled in the study. 60 patients were receiving AIs 
and 58 patients – SERMs-Tamoxifen. Patients were also divided into two 
sub groups: 1) patients with more than 3 years of last menstrual period 
(LMP) and 2) patients with less than 3 years of last menstrual period. 
Results: Among Aromatase inhibitors treated patients, there was a decrease 
in median BMD from baseline to 5 years in lumbar spine and total hip 
compared with the Tamoxifen group. No patients with normal BMD at 
baseline became osteoporotic at 5 years. Conclusion: Aromatase inhibitors 
are associated with accelerated bone loss over the 5-year treatment period. In 
postmenopausal women, treatment with tamoxifen is associated with 
preservation of the bone mineral density of the lumbar spine 
 
Keywords: Aromatase inhibitors; Selective estrogen receptor modulators; 
Bone mineral density; Dual Energy X-ray Absorptiometry; Last menstrual 
period. 
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Introduction 
 Estrogens play an important role in female bone homeostasis (Leslie, 
et al., 1995); in the estrogen deficient state, bone resorption is increased 
(Chapurlat, et al., 2000; Ettinger, et al., 1998; Rogers, et al., 2002). As a 
result of these predictable postmenopausal findings, estrogens have been 
extensively used as the main therapy to prevent bone loss in postmenopausal 
women. Estrogens reduce bone turnover rate and, as an antiresorptive, 
clearly improve bone density (Rossouw, et al., 2002) .  
 In the 10 years following the menopause, there is a reduction in BMD 
averaging 2% per annum, and osteoporosis is a major cause of morbidity in 
postmenopausal women. 
 Tamoxifen is a synthetic antiestrogen that, since its introduction for 
the treatment of patients with breast cancer in the early 1970s, has come to 
have a major role in the management of all stages of the disease (Love, et al., 
1989). More recently, tamoxifen has been proved to have a favorable effect 
on disease-free and overall survival when given as adjuvant therapy after 
primary treatment for invasive breast cancer. 
 Aromatase inhibitors: Anastrozole and Letrozole -nonsteroidal 
aromatase inhibitors are hormone therapy drugs that can slow or stop the 
growth of hormone receptor-positive tumors. They lower estrogen levels in 
the body by blocking aromatase, an enzyme that converts other hormones 
into estrogen. This prevents the cancer cells from getting the hormones they 
need to grow. 
 Aromatase inhibitors cause a loss of bone density, which leads to 
higher rates of osteoporosis and bone fractures compared to tamoxifen 
(Perez, et al., 2006; Amir, et al., 2011).  
 Tamoxifen is not a pure antiestrogen; it has some estrogen-agonist 
properties, such as the ability to decrease the serum concentrations of 
cholesterol and increase those of sex-hormone-binding globulin (Love, et al., 
1990) .  
 The beneficial effects of tamoxifen on BMD are most apparent at 
sites of trabecular bone, such as the lumbar spine (Grey, et al., 1995);  such 
protective effects are associated with decreased bone resorption and 
formation (Marttunen, et al., 1999) .  
 In our study, we report the 5-years results of adjuvant (hormonal) 
therapy on bone mineral density in Caucasia women with breast cancer.  
 
Materials and Methods 
Patients 
 118 Caucasian postmenopausal women (between 46-74 years) were 
enrolled in this study at the National Institute of Endocrinology, Metabolic 
Disorders in Georgia. The study was approved by the ethical committee of 
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the National Institute of Endocrinology according to the declaration of 
Helsinki. 
 60 patients were receiving Aromatase inhibitors - Anastrozole or 
Letrozole, 58 patients - selective estrogen receptor modulators - Tamoxifen. 
We have measured Lumbar Spine (LS) and Total Hip (TH) BMDs, values 
were obtained using Dual Energy X-ray absorptiometry (DXA).  
 38 postmenopausal women with invasive breast cancer were also 
enrolled in the study as control group. These patients were not receiving any 
treatment after primary surgery.  
 T-score > -2.5 was exclusion criteria, so patients with osteoporosis 
were not enrolled in our study. 
 
Assessments 
 Lumbar spine and Total hip BMD assessments were done at baseline, 
after 1, 2, and 5 years of therapy by dual energy x-ray absorptiometry.  
 For the lumbar spine, DXA measurement was derived by taking an 
average of the L1, L2, L3, and L4 values. Total hip BMD was calculated 
from the ratio of the total bone mineral content and bone area from the 
trochanteric, intertrochanteric, and femoral neck regions of the hip. 
  
Results 
Patients   
 60 postmenopausal Caucasian women received AI and 58 
Tamoxifen. 38 postmenopausal women (as control group) with invasive 
breast cancer not receiving any treatment after primary surgery. They all had 
a baseline DXA. 
 The mean age at entry was 56 years.  At baseline, approximately 58% 
patients from anastrozole or letrozole group, 22% patients from tamoxifen 
group and 29 % of the control group had osteopenia of the lumbar spine. 
Both treatment groups and control group had osteopenia also in total hip 
(28% in AI group; 10 % in Tamoxifen group and 21% in control group).  
 Most of the patients in the tamoxifen and the control group were 
within 3 years of menopause compared with the anastrozole and letrozole 
group. 
 
Effect of Treatment on BMD 
 Among Aromatase inhibitors treated patients, there was a decrease in 
median BMD from baseline to 5 years in lumbar spine (patients with > 3 
years of LMP -5,22% and patients with < 3 years of LMP  - 10,08%) and 
total hip (patients with > 3 years of LMP -6,52% and patients with < 3 years 
of LMP  - 6,10 % compared with the Tamoxifen group (lumbar spine : 
patients with > 3 years of LMP  +2,62 % and patients with < 3 years of LMP  
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+3,54 %; total hip: patients with > 3 years of LMP  +0,03 % and patients 
with < 3 years of LMP  +2,03 %).  No patients with normal BMD at baseline 
became osteoporotic at 5 years.  BMD changes are listed in Table 1 and 
Figure 1. 
Table 1. Percentage change in Lumbar spine and Total hip according to time since LMP 
  
Treatment groups 
Number of 
patients 
Median % change from baseline 
  
1 Year 2 Years 5 Years 
L
u
m
b
ar
 s
p
in
e 
Aromatase inhibitor 
(>3 Years since LMP) 
46 -1,61% -3,02% -5,22% 
Aromatase inhibitor 
(<3 Years since LMP)  
14 -5,01% -6,32% -10,08% 
Tamoxifen (>3 Years 
since LMP) 
16 0,87% 2,03% 2,62% 
Tamoxifen (<3 Years 
since LMP) 
42 2,01% 2,87% 3,54% 
T
o
ta
l 
h
ip
 
Aromatase inhibitor 
(>3 Years since LMP) 
46 -1,25% -3,27% -6,52% 
Aromatase inhibitor 
(<3 Years since LMP)  
14 -2,20% -3,27% -6,10% 
Tamoxifen (>3 Years 
since LMP) 
16 0,71% 1,03% 0,03% 
Tamoxifen (<3 Years 
since LMP) 
42 0,72% 1,69% 2,03% 
 
 
 
 
    
 
A 
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Fig 1. Mean percentage changes in bone mineral density after 1, 2 and 5 years.  
Lumbar spine change over time and B. total hip change over time 
 
 The control group showed changes in median BMD over the 5-year 
period (lumbar spine +1,29%; total hip +2,31%). 
 Patients with normal BMD at baseline, who received treatment 
(anastrozole or letrozole - n 60; or tamoxifen- n 58), none had become 
osteoporotic (T-score <-2.5) at 5 years. Only 3 women with osteopenia at 
baseline developed osteoporosis on AI treatment. 
 
Discussion 
 At the end of our study all BMD data showed significant bone loss in 
aromatase inhibitors treated patients relative to SERMs treated 
postmenopausal women. The rapid bone loss occurred in lumbar spine from 
baseline to 2 years compared with 2 to 5 years.  
 It is known that bone loss accelerates substantially in the late 
perimenopause and continues at a similar pace in the first postmenopausal 
years (Joel, et al., 2008). 
 We also found out that the rate of BMD loss at 1, 2, and 5 years at the 
lumbar spine for AI group was greater for women in the immediate 
postmenopausal period (within 3 years of their last menstrual period) than 
for patients more than 3 years since their menopause.  
 Breast cancer patients treated with tamoxifen showed protection 
against postmenopausal bone loss (Powles, et al., 1996). 
B 
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 We noticed that at 1, 2, and 5 years BMD increase was greater in 
Tamoxifen group patients within 3 years of their last menstrual period. 
Patients in the control group experienced little change in lumbar spine and 
total hip BMD.  
 The current analysis shows that no woman with a normal BMD at 
baseline had become osteoporotic at 5 years and the data suggest that only 
those women with a T-score of less than - 1.5 are at risk of developing 
osteoporosis during the treatment period.  
  Based on this, we can say that if pre-existing osteopenia is excluded 
no further preventive actions are required for all postmenopausal women. 
 For patients with pre-existing osteopenia (and risk factors including 
age, family history, smoking, and concomitant use of drugs such as 
corticosteroids), who are on AI treatment regular monitoring of BMD and 
bone-protection strategies are necessary.  
 Clinical trial evidence indicates that intravenous (Gnant, et al., 2009; 
Stephanie, et al., 2010; Brufsky et al., 2007)  and oral bisphosphonates 
(Delmas, et al., 1997; Lester, et al., 2008; Van Poznak, et al., 2005)  are 
effective in maintaining BMD in breast cancer patients receiving hormonal 
(endocrine) therapy. 
 Given that AIs reduce estrogen levels by approximately 90%, it 
might be expected that bone loss would be accelerated. However, it is critical 
to understand the relationship between AIs and fracture risk (Eastell, et al., 
2005). 
 Overall, findings from our study suggest that adjuvant 
anastrozole/letrozole therapy for postmenopausal women with early breast 
cancer leads to accelerated bone loss. Many studies suggest that the risk of 
developing treatment-related osteoporosis seems to be confined to those 
patients already osteopenic at baseline, and other data suggest that bone loss 
can be managed in this group by DXA scanning and use of bisphosphonates 
as needed.   
 
Conclusion 
 The present study showed that Aromatase inhibitors are associated 
with accelerated bone loss over the 5-year treatment period. The rapid bone 
loss occurred in lumbar spine from baseline to 2 years compared with 2 to 5 
years. In postmenopausal women, treatment with tamoxifen is associated 
with preservation of the bone mineral density of the lumbar spine. 
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